Franck Bonnetain is a full Professor in epidemiology and biostatistics who received a master’s degree in clinical epidemiology from School of Public Health (Nancy, France). He obtained a PhD in public health with epidemiology and statistics specialties in 2005 as well asthe “Habilitation à diriger des recherches” (Professoral capability) in 2010. 



After working as epidemiologist for 3 years in Dijon for the “Institut de Veille Sanitaire”, he served as epidemiologist and biostatistician for the design, analyses and interpretation of clinical trials in Oncology. He was head of the methodology unit of French Federation of Digestive Cancerology (FFCD) and as head of methodology and quality of life unit of Georges François Leclerc Cancer care center from 2003 to 2012 (Dijon, France). Finally in September 2012 he was nominated as Professor in biostatistics, epidemiology, public health and quality of life in oncology at the university hospital of Besançon. He took the head of the methodology and quality of life in oncology unit.

In 2009, he launched and was co-founder of the French national clinical research plateform “Quality of life and cancer”.

He teaches statistics, epidemiology, methodology of clinical trials and quality of life in medical and pharmaceutical school as well as for master degree.


Research thematic:

 Definition, selection and validation of endpoints used in oncology clinical trials 

Health related quality of life and other Patient reported outcome in oncology

Design of clinical trials and epidemiological studies in oncology

Development of prognostic and predictive scoring system


Main areas of expertise:

- Methodology Statistics and clinical epidemiology

- Clinical trial and clinical research

- Quality of life

- Patient reported outcome

- Oncology

- Digestive Oncology

- Consensus methodology

- Supportive care


Main ongoing external collaborations:


- Full Member of EORTC QoL group since 2010 and board of Probe project since 2014

- Member of ARCAD Clinical Trials Program (http://arcad.marcelww.com/nos-actions/programmes-de-recherche/arcad-clinical-trials-program) and co-head of pancreatic cancer meta-analysis

- Head of DATECAN initiative (internal consensus for the definition of composite endpoints used in oncology clinical trials)

- Head of methodology of GERCOR since 2009 and member of PRODIGE group - Secretary of the AFSOS-UNICANCER French national supportive care group since 2013

- Referent Methodologist expert for GERICO (Geriatric oncology trials in France) and GI group of Unicancer

- Board of ANOCEF since 2010 (Association des neuro-oncologues d’expression française)

- Member of Cochrane lung cancer


Tools online

- Prognostic Score and Nomogram to Predict Overall Survival in Locally Advanced Pancreatic Cancer: The PROLAP score (mettre un lien qui renvoit sur l’outil)

Main publications

sample

AbstractBACKGROUND:The combination of an anti-VEGF or an anti-EGFR-targeted monoclonal antibody with chemotherapy has...

Posted by : Pr. Franck BONNETAIN, Dr. Dewi VERNEREY
Journal name : Lancet Oncol

sample

AbstractPURPOSE:The MOSAIC (Multicenter International Study of Oxaliplatin/Fluorouracil/Leucovorin in the Adjuvant...

Posted by : Dr. Dewi VERNEREY, Pr. Franck BONNETAIN
Journal name : JCO

sample

Background: In advanced pancreatic ductal adenocarcinoma (aPDAC), there is no consensual strategy for second-line...

Posted by : Dr. Dewi VERNEREY, Pr. Franck BONNETAIN, Mme. Aurelia MEURISSE
Journal name : JNCI J Natl Cancer Inst

Latest publications

OBJECTIVES: We conducted a prospective study approved by the local ethics committee to determine the impact of a...

Posted by : Pr. Franck BONNETAIN, Dr. Amélie ANOTA
Journal name : Annales pharmaceutiques françaises

sample

BackgroundEven if a large majority of out-of-hospital cardiac arrest (OHCA) survivors appear to have a good neurological...

Posted by : Pr. Franck BONNETAIN
Journal name : Resuscitation

sample

PurposeWe previously showed that a sequential chemotherapy with dose-dense oxaliplatin (FOLFOX7)and irinotecan (FOLFIRI;...

Posted by : Pr. Franck BONNETAIN
Journal name : PLOS ONE

sample

AbstractBackground:Pancreatic adenocarcinoma (PDAC) incidence is increasing worldwide. Several studies have shown...

Posted by : Dr. Dewi VERNEREY, Pr. Franck BONNETAIN
Journal name : BMC Cancer

sample

AbstractPURPOSE:The MOSAIC (Multicenter International Study of Oxaliplatin/Fluorouracil/Leucovorin in the Adjuvant...

Posted by : Dr. Dewi VERNEREY, Pr. Franck BONNETAIN
Journal name : JCO

sample

Background: Deficient mismatch repair (dMMR) colon cancer (CC) is reportedly resistant to 5-fluorouracil (5FU) adjuvant...

Posted by : Pr. Franck BONNETAIN, Dr. Dewi VERNEREY, Dr. Guillaume MOUILLET
Journal name : JNCI Journal of the National Cancer Institure

sample

Background:To assess the efficacy of a patient educational program built according to guidelines that aims at reducing...

Posted by : Pr. Franck BONNETAIN, Dr. Amélie ANOTA
Journal name : British Journal of Cancer

sample

AbstractGlioblastoma is the most common malignant brain tumor in adults. Baselinehealth-relatedquality of life (HRQoL)...

Posted by : Mr. Brice PAQUETTE, Dr. Dewi VERNEREY, Dr. Amélie ANOTA, Pr. Franck BONNETAIN
Journal name : Cancer Medicine

sample

Background: Medical progress and the lifestyle modification have prolonged life expectancy, despite the development of...

Posted by : Pr. Franck BONNETAIN, Dr. Amélie ANOTA, Mme. Morgane CHOTARD, Mme. Audrey FOUBERT, Mme. Astrid POZET
Journal name : Trials

sample

Purpose Eastern Cooperative Oncology Group Performance Status (ECOG-PS) is currently an important parameter in the...

Posted by : Pr. Franck BONNETAIN
Journal name : Quality of Life Research

Latest News

Latest tools

The R package QoLR allows to compute the scoring of main EORTC quality of life questionnaires and to perform the...

Posted by : Pr. Franck BONNETAIN, Dr. Amélie ANOTA

The R package QoLR allows to compute the scoring of main EORTC quality of life questionnaires and to perform the...

Posted by : Dr. Amélie ANOTA, Dr. Dewi VERNEREY, Dr. Amélie ANOTA, Pr. Franck BONNETAIN, Dr. Amélie ANOTA

The management of locally advanced pancreatic cancer (LAPC) patients remains controversial. Better discrimination for...

Posted by : Pr. Franck BONNETAIN, Dr. Sophie PAGET-BAILLY, Dr. Dewi VERNEREY

MRQoL is a package that consists of three functions which allows us to calculate the Minimal Clinically Important...

Posted by : Pr. Franck BONNETAIN, Dr. Amélie ANOTA, Mr. Ahmad OUSMEN

The R package QoLR allows to compute the scoring of main EORTC quality of life questionnaires and to perform the...

Posted by : Dr. Amélie ANOTA, Dr. Dewi VERNEREY, Dr. Amélie ANOTA, Pr. Franck BONNETAIN, Dr. Amélie ANOTA

Communication from Pr Bonnetain at the 2nd EORTC Cancer Clinical Research Methodology Course for Patient Advocates,...

Posted by : Pr. Franck BONNETAIN

Posted by : Pr. Franck BONNETAIN, Dr. Dewi VERNEREY

Discover Pr Bonnetain's keynote during the canceropôle IDF' seminar on rare tumours.Listen to the keynote here.Discover...

Posted by : Dr. Sophie PAGET-BAILLY, Pr. Franck BONNETAIN

Randomized Phase II Study of Weekly ABI-007plus Gemcitabine or Simplified LV5FU2 as FirstlineTherapy in Patients with...

Posted by : Pr. Franck BONNETAIN

2015-2017 © Copyright - UMQVC.org

Website by Pearlweb